Effects of cyclocreatine in rat hepatocarcinogenesis model

Anticancer Research

Volumn 20, Issue 3 A, 2000, Pages 1627-1633

  Jeong, Kyu Shik ^a   Park, Sang Joon ^b   Lee, Cha Soo ^b   Kim, Tae Whan ^c   Kim, Sung Ho ^d   Ryu, Si Yun ^e   Williams, Bruce H ^f   Veech, Richard L ^f   Lee, Yun Sil ^c  

^a NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM   (United States)

^b Kyungpook National University   (South Korea)

^c Korea Cancer Center Hospital   (South Korea)

^d Chonnam National University   (South Korea)

^e Chungnam National University   (South Korea)

^f ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

Author keywords

Apoptosis; Cyclocreatine; Diethylnitrosamine; Glutathione S transferase placentral form (GST P); Hepatocarcinogenesis

Indexed keywords

BROMETHOL; CYCLOCREATINE; DIETHYLNITROSAMINE; GLUTATHIONE TRANSFERASE; N (2 FLUORENYL)ACETAMIDE; PLACENTA ENZYME; SODIUM CHLORIDE; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL FOOD; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CHEMICAL CARCINOGENESIS; CONTROLLED STUDY; FEMALE; LIVER CARCINOGENESIS; NONHUMAN; PARTIAL HEPATECTOMY; PRIORITY JOURNAL; RAT;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL TRANSFORMATION, NEOPLASTIC; CREATININE; DISEASE MODELS, ANIMAL; FEMALE; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; LIVER NEOPLASMS, EXPERIMENTAL; RATS; RATS, INBRED F344;

EID: 0033854932     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Hosokawa S, Tatematsu M, Aoki T, Nakanowatari J, Lgarashi T and Ito N: Modulation of diethylnitrosamine-initiated placental glutathione S-transferase positive preneoplastic and neoplastic lesions by clofibrate, a hepatic peroxisome proliferator. Carcinogenesis 10: 2237-2241, 1989.
2. Fairchild CR, Ivy SP, Rushmore T, Lee G, Koo P, Goldsmith ME, Myers CE, Farber E and Cowan KH: Carcinogen-induced mdr over-expression is associated with xenobiotic resistance in rat preneoplastic liver nodules and hepatocellular carcinomas. Proc Natl Acad Sci U.S.A. 84: 7701-7705, 1987.
3. Jakoby WB: The glutathione S-transferase: a group of multifunctional detoxification proteins. Adv Enzymol Relat Areas Mol Biol 47: 384-414, 1977.
4. Kramer RA, Zakher J and Kim G: Role of the glutathione redox cycle in acquired and de novo multi-drug resistance. Science 241: 694-697, 1988.
5. Dragan YP, Rizvi T, Xu YH, Hully JR, Bawa N, Campbell HA, Maronpot RR and Pitot HC: An initiation-promotion assay in rat liver as a potential complement to the 2-year carcinogenesis bioassay. Fund Applied Toxicol 16: 525-548, 1991.
6. Sato K, Kitahara A, Satoh K, Ishigawa T, Talematsu M and Ito N: The placental form of glutathione S-transferase as a new marker protein for preneoplasia in rat chemical hepatocarcinogenesis. Gann 75: 199-202, 1984.
7. Yamamoto K, Yokose Y, Kakajima A, Eimoto H, Shiraiwa K, Tamura K, Tsutsumi M and Konishi Y: Comparative histochemical investigation of the glutathione S-transferase placental form and (-glutamyltranspeptidase during N-nitrosobis (2-hydroxypropyl) amine)induced lung carcinogenesis in rats. Carcinogenesis 9: 399-404, 1988.
8. Moore MA, Satoh K, Kitahara A, Sato K and Ito N: A protein cross-reacting immunohistochemically with rat glutathione S-transferase placental form as a marker for preneoplasia in Syrian hamster pancreatic and hepatocarcinogenesis. Gann 76: 1-4, 1985.
9. Mannervik B, Castro VM, Danielson UH, Tahir MK, Hasson J and Ringborg U: Expression of class Pi glutathione transferase in human tumor cell lines. Cancer Res 48: 527-533, 1985.
10. Tsuchida S, Sekine Y, Shineha R, Nischihira T and Sato K: Elevation of the placental glutathione S-transferase form (GST-P) in tumor tissues and the levels in sera of patients with cancer. Cancer Res 49: 5225-5229, 1989.
11. Ito N, Tsuda H, Tatematsu M, Inoue T, Tagawa Y, Aoki T, Uwagawa S, Kagawa M, Orgiso T, Masui T, Imaida K, Fukushima S and Asamoto M: Enhancing effect of various hepatocarcinogens on induction of preneoplastic glutathione S-transferase placental form positive foci in rats -an approach for a new medium-term bioassay system. Carcinogenesis 9: 387-394, 1988.
12. Ito N, Imaida K, Hasegawa R and Tsuda H: Rapid bioassay methods for carcinogens and modifiers of hepatocarcinogenesis. CRC Crit Rev Toxicol 19: 385-415, 1989.
13. Ito N and Imaida K: Strategy of research for cancer chemoprevention. Teratog Carcinog Mutagen 12: 79-95, 1992.
14. Hasegawa R and Ito N: Liver medium-term bioassay in rats for screening of carcinogens and modifying factors in hepatocarcinogenesis. Food Chem Toxicol 30: 979-992, 1992.
15. Wallimann T, Wyss M, Brdiczka D, Nicolay K and Eppenberger HM: Intracellular compartmentaton, strucutre and function of creatine kinase isoenzymes in tissues with high and fluctuating energy demands: the "phosphocreatine circuit" for cellular energy homeostasis. Biochem J 281: 12-40, 1992.
16. Bessman SP and Geiger PJ: Transport of energy in muscle: the phosphocreatine shuttle. Science 211: 448-452, 1981.
17. McLaughlin AC, Cohn M and Kenyon GL: Specificity of creatine kinase for guanidino substrates, kinetic and proton nuclear magnetic relaxation rate studies. J Biol Chem 247: 4382-4388, 1972.
18. Veech RL, Lawson JWR, Cornell NW and Krebs HA: Cytosolic phosphorylation potential. J Biol Chem 254: 6536-6547, 1979.
19. Martin KJ, Winslow ER and Kaddurah-Daouk R: Cell cycle studies of cyclocreatine, a new anti-cancer agent. Cancer Res 54: 5160-5165, 1994.
20. Hoosein NM, Martin KJ, Abdul M, Logothetis CJ and Kaddurah-Daouk R: Antiproliferative effects of cyclocreatine on human prostatic carcinoma cells. Anticancer Res 15: 1339-1342, 1995.
21. Miller EE, Evans AE and Cohn M: Inhibition of rate of tumor growth by creatine and cyclocreatine. Proc Natl Acad USA 90: 3304-3308, 1993.
22. Lillie JW, O'Keefe M, Valinski H, Hamlin HA Jr, Varban ML and Kaddurah-Daouk R: Cyclocreatine (1-carboxymethyl-2-iminoimida-zolidine) inhibits growth of a broad spectrum of cancer cells derived from solid tumors. Cancer Res 55: 3172-3178, 1993.
23. Matthews RT, Yang L, Genkins BG. Ferrante RJ, Rosen BR, Kaddurah-Daouk R and Flint-Beal M: Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease. J Neuroscience 18: 156-163, 1998.
24. + cotransport in human breast cancer cells: mechanism of activity. Am J Physiol 277: C708-C716, 1999.
25. Annesley TM and Walker JB: Cyclocreatine phosphate as a substitute for creatine phosphate in vertebrate tissues. Energetic considerations. Biochem Biophys Res Commun 74: 185-190, 1977.
26. LoPresti P and Cohn M: Direct determination of creatine kinase equilibrium constants with creatine or cyclocreatine substrate. Biochim Biophys Acta 998: 317-320, 1989.
27. BB) in the liver. Biochem J 303: 531-538, 1994.
28. Walker JB: Creatine: biosynthesis, regulation and function. Adv Enzymol Relat Areas Mol Biol 50: 177-242, 1979.
29. Wiseman RW and Kushmerick MJ: Creatine kinase equilibration follows solution thermodynamics in skeletal muscle. J Biol Chem 270: 12428-12438, 1995.
30. Sato K, Kitahara A, Satoh K, Ishigawa T. Tatematsu M and Ito N: The placental form of glutathionc S-transferase as a new marker protein for preneoplasia in rat chemical hepatocarcinogenesis. Gann 75: 199-202, 1984.
31. Faber E: The biochemistry of preneoplastic livers: A common meta-bolic pattern in hepatocyte nodules. Can J Biochem Cell Biol 62: 486-494, 1984.
32. Becker S and Schneider F: Investigations on the function of creatine kinase in Ehlrich ascites tumor cells. Biol Chem Hoppe-Seyler 370: 357-364, 1989.
33. Lillie JW, O'Keefe M, Valinski H, Hamlin HA, Varban ML and Kaddurah-Daouk R: Cyclocreatine (1-carboxymethyl-2-iminoimida-zolidine) inhibits growth of a broad spectrum of cancer cells derived from solid tumors. Cancer Res 53: 3172-3178, 1993.
34. Miller EE, Evans AE and Cohn M: Inhibition of rate tumor growth by creatine and cyclocreatine. Proc Natl Acad Aci USA 90: 3304-330S, 1993.
35. Martin KJ. Vassalo CD, Teicher BA and Kaddurah-Daouk R: Microtubule stabilization and potentiation of taxol by the creatine analog cyclocreatine. Anticancer Drugs 6: 419-426, 1995.
36. Bergnes G, Yuan W, Khandekar VS, O'Keefe MM, Martin KJ, Teicher BA and Kaddurah-Daouk R: Creatine and phosphocreatine analogs: anticancer activity and enzymatic analysis. Oncol Res 8: 121-130, 1996.
37. Mulvaney PT, Stracke ML, Nam SW. Woodhouse E, O'Keefe M, Clair T, Liotta LA, Khaddurah-Daouk R and Schiffmann E: Cyclocreatine inhibits stimulated motility in tumor cells possessing creatine kinase. Int J Cancer 78: 46-52, 1998.
38. Phillips GN, Thomas JW, Annesley TM and Quiocho FA: Stereo-specificity of creatine kinase. Crystal structure of 1-carboxymethyl-2-imino-3-phosphonoimidazolidine. J Am Chem Soc 101: 7120-7121, 1979.
39. Wallimann T, Wyss M, Brdiczka D, Nicolay K and Eppenberger HM: Intracellular compartmentation, structure and function of creatine kinase isoenzymes in tissues with high and fluctuating energy demands: the "phosphocreatine circuit" for cellular energy homeostasis. Biochem J 281: 21-40, 1992.
40. 2+ responses in muscles with combined mitochondrial and cytosolic ereatine kinase deficiencies. Cell 89: 93-103, 1997.
41. Annesley TM and Walker JB: Cyclocreatine phosphate as a substitute for ereatine phosphate in vertebrate tissues. Energetic considerations. Biochem Biophys Res Commun 74: 185-190, 1977.
42. Cowan KH, Batist G, Tulpule A, Sinha BK and Myers CE: Similar biochemical changes associated with multi-drug resistance in human breast cancer cells and carcinogen-induced resistance to xenobiotics in rats. Proc Natl Acad Sci 83: 9328-9332, 1986.
43. Michalopoulos GK and DeFrances MC: Liver regeneration. Science 276: 60-66, 1997.